Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer

被引：0
|
作者：
Cucevic, B
Samarzija, M
Baricevic, D
Jakopovic, M
Redzepi, G
Samija, M
机构：
[1] Univ Zagreb, Univ Hosp Lung Dis Jordanovac, HR-10002 Zagreb, Croatia
[2] Univ Zagreb, Univ Hosp Tumors, HR-10002 Zagreb, Croatia
来源：
COLLEGIUM ANTROPOLOGICUM | 2005年 / 29卷 / 02期
关键词：
gemcitabine; lung cancer; NSCLC; chemotherapy;
D O I：
暂无
中图分类号：
Q98 [人类学];
学科分类号：
030303 ;
摘要：
Aim of this study was to estimate efficacy of gemcitabine in first and the second-line chemotherapy for patients with advanced non-small cell lung cancer (stage III and TV). In first-line chemotherapy, 120 patients were treated with different chemotherapy regimens. Fifty-nine patients were treated with gemcitabine / cisplatin (PG), 41 with cisplatin I etoposide (PE) and 20 with mitomycin / ifosamide / cisplatin (MIC). Forty patients, unsuccessfully treated with PE and MIC in first-line therapy were treated with PG (24 pts) and with best supportive care (BSC) (16 pts). In first-line therapy PG was superior to PE and MIC protocol (mean survival (MS) 10 vs. 7 vs. 8.5 months). Response rate (RR) for PG in first-line therapy was 46% and 21% in second-line. We showed also significantly better survival in patients treated with PG in second-line chemotherapy comparing to best supportive care (MS 9 us. 5.5 months). Toxic side effects for combination PG was acceptable. This study confirmed that PG combination is safe and effective as first and seeond-line chemotherapy for patients with advanced non-small cell lung cancer.
引用
收藏
页码：583 / 588
页数：6
相关论文
共 50 条
  • [31] Advanced non-small cell lung cancer. Maintenance and second-line treatment
    Schuette, W.
    Nagel, S.
    Haak, G.
    Steinert, M.
    [J]. PNEUMOLOGE, 2012, 9 (01): : 43 - 48
  • [32] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [33] Second-line treatment for advanced non-small cell lung cancer:: A systematic review
    Barlési, F
    Jacot, W
    Astoul, P
    Pujol, JL
    [J]. LUNG CANCER, 2006, 51 (02) : 159 - 172
  • [34] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [35] Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
    Reckamp, Karen L.
    [J]. CANCER LETTERS, 2012, 321 (02) : 101 - 109
  • [36] A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
    Kotsakis, Athanasios
    Hatzidaki, Dora
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Bozionelou, Vasiliki
    Androulakis, Nikolaos
    Kalbakis, Kostas
    Saridaki, Zacharenia
    Georgoulias, Vassilis
    Agelaki, Sophia
    [J]. ANTICANCER RESEARCH, 2010, 30 (10) : 4335 - 4342
  • [37] A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
    Sculier, JP
    Lafitte, JJ
    Berghmans, T
    Thiriaux, J
    Lecomte, J
    Efremidis, A
    Ninane, V
    Paesmans, M
    Mommen, P
    Klastersky, J
    [J]. LUNG CANCER, 2000, 29 (01) : 67 - 73
  • [38] First- and second-line biomarker utilization in non-small cell lung cancer
    Leong, Matthew
    Azimpouran, Mahzad
    McCloskey, Audrey
    Sankar, Kamya
    Vail, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Oral second-line chemotherapy for advanced non-small-cell lung cancer: The bottom line
    Gandara, David R.
    Davies, Angela M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2700 - 2701
  • [40] Second-line chemotherapy with gemcitabine and uracil/tegafur for relapsed or refractory non-small cell lung cancer: a phase II study
    Tanaka, H.
    Tanaka, J.
    Itoh, R.
    Kuriyama, H.
    Kagamu, H.
    Itoh, K.
    Sato, K.
    Nakata, K.
    Gejyo, F.
    Yoshizawa, H.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375
12345